We provides a novel approach to generate low-temperature atomic oxygen anions (O-) emission using the cesium oxide-doped 12CaO.7Al2O3 (Cs2O-doped C12A7). The maximal emission intensity of O- from the Cs2O-doped C1...We provides a novel approach to generate low-temperature atomic oxygen anions (O-) emission using the cesium oxide-doped 12CaO.7Al2O3 (Cs2O-doped C12A7). The maximal emission intensity of O- from the Cs2O-doped C12A7 at 700℃ and 800 V/cm reached about 0.54μA/cm2, which was about two times as strong as that from the un-doped C12A7 (0.23 μA/cm2) under the same condition. The initiative temperature of the O- emission from the Cs2O-doped C12A7 was about 500 ℃, which was also much lower than the initiative temperature from the un-doped C12A7 (570 ℃) in the given field of 800 V/cm. High pure O- emission close to 100% could be obtained from the Cs2O-doped C12A7 under the lower temperature (〈550℃). The emission features of the Cs2O-doped C12A7, including the emission distribution, temperature effect, and emission branching ratio have been investigated in detail and compared with the un-doped C12A7. The structure and storage characteristics of the resulting material were also investigated via X-ray diffraction and electron paramagnetic resonance. It was found that doping Cs2Oto C12A7 will lower the initiative emission temperature and enhance the emission intensity展开更多
We developed an H5/H7 trivalent inactivated vaccine by using Re-11, Re-12, and H7-Re2 vaccine seed viruses, which were generated by reverse genetics and derived their HA genes from A/duck/Guizhou/S4184/2017(H5N6) (DK/...We developed an H5/H7 trivalent inactivated vaccine by using Re-11, Re-12, and H7-Re2 vaccine seed viruses, which were generated by reverse genetics and derived their HA genes from A/duck/Guizhou/S4184/2017(H5N6) (DK/GZ/S4184/17) (a clade 2.3.4.4d virus), A/chicken/Liaoning/SD007/2017(H5N1) (CK/LN/SD007/17) (a clade 2.3.2.1d virus), and A/chicken/ Guangxi/SD098/2017(H7N9) (CK/GX/SD098/17), respectively. The protective efficacy of this novel vaccine and that of the recently used H5/H7 bivalent inactivated vaccine against different H5 and H7N9 viruses was evaluated in chickens. We found that the H5/H7 bivalent vaccine provided solid protection against the H7N9 virus CK/GX/SD098/17, but only 50–60% protection against different H5 viruses. In contrast, the novel H5/H7 trivalent vaccine provided complete protection against the H5 and H7 viruses tested. Our study underscores the importance of timely updating of vaccines for avian influenza control.展开更多
基金This work is supported by the National Natural Science Foundation of China (No.50772107), the National High Tech Research and Development Program (No.2009AA05Z435), and the National Basic Research Program of the Ministry of Science and Technology of China (No.2007CB210206).
文摘We provides a novel approach to generate low-temperature atomic oxygen anions (O-) emission using the cesium oxide-doped 12CaO.7Al2O3 (Cs2O-doped C12A7). The maximal emission intensity of O- from the Cs2O-doped C12A7 at 700℃ and 800 V/cm reached about 0.54μA/cm2, which was about two times as strong as that from the un-doped C12A7 (0.23 μA/cm2) under the same condition. The initiative temperature of the O- emission from the Cs2O-doped C12A7 was about 500 ℃, which was also much lower than the initiative temperature from the un-doped C12A7 (570 ℃) in the given field of 800 V/cm. High pure O- emission close to 100% could be obtained from the Cs2O-doped C12A7 under the lower temperature (〈550℃). The emission features of the Cs2O-doped C12A7, including the emission distribution, temperature effect, and emission branching ratio have been investigated in detail and compared with the un-doped C12A7. The structure and storage characteristics of the resulting material were also investigated via X-ray diffraction and electron paramagnetic resonance. It was found that doping Cs2Oto C12A7 will lower the initiative emission temperature and enhance the emission intensity
基金This work was supported by the National Key R&D Program of China(2016YFD0501602,2017YFD0500701,and 2016YFEO203200)the National Natural Science Foundation of China(3167131307)+1 种基金the China Agriculture Research System(CARS-41-G12)and Central Publicinterest Scientific Institution Basal Research Fund(1610302017001).
文摘We developed an H5/H7 trivalent inactivated vaccine by using Re-11, Re-12, and H7-Re2 vaccine seed viruses, which were generated by reverse genetics and derived their HA genes from A/duck/Guizhou/S4184/2017(H5N6) (DK/GZ/S4184/17) (a clade 2.3.4.4d virus), A/chicken/Liaoning/SD007/2017(H5N1) (CK/LN/SD007/17) (a clade 2.3.2.1d virus), and A/chicken/ Guangxi/SD098/2017(H7N9) (CK/GX/SD098/17), respectively. The protective efficacy of this novel vaccine and that of the recently used H5/H7 bivalent inactivated vaccine against different H5 and H7N9 viruses was evaluated in chickens. We found that the H5/H7 bivalent vaccine provided solid protection against the H7N9 virus CK/GX/SD098/17, but only 50–60% protection against different H5 viruses. In contrast, the novel H5/H7 trivalent vaccine provided complete protection against the H5 and H7 viruses tested. Our study underscores the importance of timely updating of vaccines for avian influenza control.